Early Stage Trial Shows An Experimental Flu Vaccine Can Provide Immunity Against All Strains Of Flu

Kathleen Kinder
Kathleen Kinder

Updated · Dec 12, 2020

SHARE:

News.Market.us is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
close
Advertiser Disclosure

At Market.us News, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us News. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Health experts start worrying that the existing flu vaccine might not be effective in circulating strain of the flu virus when the season is around the corner each year. However, an early-stage trial has shown a new experiment might be able to solve this issue. The study has found that a universal flu vaccine might be able to protect against all strains of flu. This vaccine has sparked a potent immune response and has shown no side effects that the existing seasonal flu vaccine has. The findings of the trial have been released in a journal called Nature Medicine. Experts have said that for the first time, a phase 1 trial in humans has observed a rationally designed flu vaccine, which can protect against all types of seasonal flu and has the ability to protect against a flu pandemic as well. The co-author of the study Florian Krammer has said that the findings of the study show that it is possible to design a vaccine in a more rational way to get broader protection.

Experts have said that if a universal flu vaccine continues to show great results in phase 2 and phase 3 trials as well, it will require approval from the US Food and Drug Administration (FDA). This vaccine will put an end to yearly flu shots. As per the experts, people will require two or three doses of a universal flu vaccine initially and they will be protected for years. Florian Krammer has said that due to the funding crunch for the research, it still can take many years before these flu shots are available. As per the data, flu shots are not as efficient as vaccines, although, even a poorly matched vaccine can reduce the risk of severe illness due to flu. The data from the US Center for Disease Control and Prevention (CDC) has reported that during the recent flu season, flu shots have been nearly 45 percent effective against the two main influenza strains, which have been spreading. Existing flu shots do not work well because the vaccines are designed to target a part of the virus, which involves mutation. Experts have said that the strain of the virus during flu season 2020 has been different from the flu virus in 2019.

The new universal vaccine or Mt. Sinai vaccine targets a different part of the virus than other flu shots. Experts have revealed that the surface of the virus is dusted with little prongs, which have a mushroom or tulip-like structure. At the top of the virus, there is a head and below there is a stem or more technically a stalk. Earlier, scientists have been making a flu vaccine, which is designed to trigger the immune system to target the protein found on the head of the virus. This protein is responsible for the mutation of the flu virus. It makes sense, as the immune system looks for this protein while identifying the invaders. The stalk of the virus does not change over time, which makes it a better target for the immune system. However, the immune system does not pay much attention to this part of the virus, which has a certain kind of protein in it. Krammer has said that they have found a way to train the immune system to focus on a protein found in the stalk. Krammer and his teammates have come up with a chimeric vaccine, which has been made from proteins of two different types of viruses. Experts have mixed a protein from the head of the avian flu with the stalk of human flu. They have stated that the immune system is familiar with the stalk of various human flu viruses but they are targeted to attract the head part of the virus. The immune system will respond preferentially, once the stalk is combined with an exotic head of the virus.

SHARE:
Kathleen Kinder

Kathleen Kinder

With over 4 years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.